Incidents with IV ambulatory chemotherapy, including the death of a patient in 2006 due to a fluorouracil overdose in Edmonton, have highlighted the safety risks of this particular therapy. Sponsored by the Canadian Patient Safety Institute (CPSI), the Canadian Association of Provincial Cancer Agencies (CAPCA), the Institute for Safe Medication Practices (ISMP) Canada, and five provincial cancer care agencies, HumanEra conducted a pan-Canadian research study with the following objectives:
Multiple methodologies were employed to achieve these objectives, including a national survey of cancer care providers, field studies in six cancer treatment facilities across Canada and in-depth idenfication and analyses of key safety themes.
Knowledge Translation and Uptake
Outputs from the study included:
Deliverables were circulated widely across Canada through conference presentations and webinars to over 2,000 participants, targeted mail-outs, manufacturer distribution, and peer-reviewed publications. Practice changes are now underway in centres all over Canada as a direct result of this research. Recommendations have been incorporated into Accreditation Canada standards and other professional practice guidelines. A manufacturer is adapting materials for an international audience. This study has served as the impetus for further research pertaining to the work processes and safety of pharmacy admixtur and has been unmatched in the scope of its interdisciplinary and inter-jurisdictional collaboration and its proactive approach to patient safety.
Canadian Patient Safety Institute (CPSI)
BC Cancer Agency (BCCA)
Alberta Cancer Board (ACB)
CancerCare Manitoba (CCMB)
CancerCare Ontario (CCO)
New Brunswick Cancer Network (CCNB)
Canadian Association of Provincial Cancer Agencies (CAPCA)
University Health Network (UHN)
Debbie Chan (student)